Speaking to Outsourcing-Pharma Michael Wilhelm, CEO of ImmuneRegen, explained that his company is “very excited” to work with Azopharma and has been impressed by the diligence of the contract research organisation (CRO).
Giving an example Wilhelm said that ImmuneRegen had anticipated it taking nine to 12 months to complete toxicology and pharmacokinetic (PK) work in preparation for Phase I but Azopharma has put in a six to nine month timeline.
Azopharma also moved quickly when offered the chance to acquire equity in ImmuneRegen, according to Wilhelm who explained that he had approached two other CROs but they were slower to act.
The CRO will now work to develop Homspera, ImmuneRegen’s lead candidate, providing manufacturing, formulation development and safety studies as it approaches its investigational new drug (IND) application.
Once a therapeutic enters the clinic it receives increased attention from potential partners, according to Wilhelm who added that ImmuneRegen has relationships with big pharmas that may be interested in the treatment.
Selection of Azopharma
Azopharma did some early work with ImmuneRegen but the catalyst for the latest deal was when the CRO contacted the biotech as part of its efforts to reach out to potential clients.
ImmuneRegen believes that the breadth of Azopharma’s development services and experience of inhaled drugs and medical devices make the CRO a suitable collaborator.
The biotech has also contracted Bachem to be the primary manufacturer of Homspera and is nearing completion of a capital raising effort.